查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864420

金諾芬市場依適應症、治療領域、通路、最終用戶和劑型分類－2025-2032年全球預測

Auranofin Market by Indication, Therapeutic Class, Distribution Channel, End User, Dosage Strength - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，金諾芬市場規模將成長至 3.2296 億美元，複合年成長率為 4.97%。

關鍵市場統計數據
基準年 2024 2.1899億美元
預計年份：2025年 2.3002億美元
預測年份 2032 3.2296億美元
複合年成長率 (%) 4.97%

金諾芬在腫瘤學和類風濕性關節炎的重新定位表明，跨學科合作為改善治療研發和療效提供了機會。

由於其在治療領域擁有悠久的成功歷史，金諾芬（auranofin）因臨床療效的提升和藥理機制的日益清晰而重新受到關注。金諾芬最初是為治療風濕病而研發和上市的，但其潛在的抗癌和免疫調節特性使其作用機制備受矚目。這種重新定位促使包括臨床研究人員、藥品目錄委員會、生產者和支付方在內的眾多相關人員重新評估金諾芬在現代治療模式中的地位。

隨著臨床計畫的推進，該藥物的特性正沿著兩條平行路徑進行檢驗：一是其在免疫介導疾病中的持續效用，二是其在腫瘤治療領域的拓展。這種雙軌並行的發展路徑促使人們對給藥策略、安全性監測以及其相對於其他治療層級的定位進行新的考慮。同時，不斷變化的監管預期和支付方的審查也在影響研發策略和證據產生計畫。

整體而言，這些趨勢既帶來了機遇，也帶來了挑戰。與奧拉諾芬相關的機構必須權衡對強力的臨床檢驗的需求與實際需要，例如可靠的供應、合理的配送計劃以及與臨床醫生和患者清晰的價值溝通。本導言闡述了為何對奧拉諾芬的重新評估需要在臨床、營運和准入等領域進行周密的策略規劃。

科學進步、監管政策變化和商業趨勢共同作用，重新定義了奧拉諾芬的臨床定位和研究設計重點。

金諾芬的市場格局正在經歷多重變革，涵蓋科學、監管和商業性應用等多個面向。在科學方面，我們對氧化還原生物學、蛋白質穩態和免疫調節的理解不斷深入，揭示了金諾芬潛在的作用機制，使其療效可望超越最初的適應症。這些機制方面的新發現與更先進的生物標記和轉化模型的開發相輔相成，共同塑造現代臨床項目和假設驅動型試驗的設計。

對於重新定位的藥物，監管路徑也正在進行重要的調整。監管機構越來越鼓勵採用適應性試驗設計並整合真實世界數據，前提是安全性特徵得到充分闡明，這為申辦方設定了路徑和預期。同時，對獲益風險平衡和成本效益的日益重視意味著，證據策略必須從早期階段就與支付方和臨床醫生的需求緊密結合。

在商業方面，分銷物流、籌資策略和製造商合作關係的變化正在影響研發人員對規模化生產和市場准入的思考。從許可協議到契約製造關係等策略聯盟為供應安全提供了保障，而共同研究模式則有助於快速檢驗新的適應症。這些科學、監管和商業性的綜合變化正在重新定義相關人員如何優先考慮投資和分配資源，以支持下一代金諾芬計畫。

預計美國將於2025年調整關稅，及其對奧拉諾芬供應鏈韌性、採購成本和臨床試驗營運的影響

美國計劃於2025年調整關稅政策，將對包括奧拉諾芬在內的藥品供應鏈產生影響，尤其是從國際採購活性藥物成分、包裝材料和輔助材料的藥品。關稅調整將改變製造商和合約合作夥伴的採購經濟效益，促使他們重新評估其採購基礎、供應商協議和庫存策略。這些營運應對措施通常會與增強自身韌性和降低對單一來源依賴的措施同步進行。

臨床研究營運也會受到進出口成本波動的影響。原料和成品關稅的增加會影響研究預算和物流，尤其是依賴集中式供應鏈的多中心研究。申辦方可能需要調整出貨計畫、尋找替代供應商並制定額外的緊急時應對計畫，以確保研究按時完成並確保資料完整性。重點，籌資策略的多元化和近岸外包可以降低波動風險，但實施這些策略需要前置作業時間。

最後，採購成本壓力可能會影響藥品目錄的編制決策和醫院的採購協議，進而對支付者和醫療服務提供者產生下游影響。因此，考慮擴大和廣泛應用金諾芬的機構應將關稅相關因素納入其供應計劃、合約談判和臨床營運中，並制定緊急應變計畫，以確保醫療服務的連續性和研究的持續性。

關鍵細分市場分析重點關注奧拉諾芬臨床應用的促進因素，並按適應症、治療類別、通路和劑量進行市場定位。

細分市場層面的趨勢為理解如何在臨床和營運環境中評估和部署金諾芬提供了重要的背景資訊。按適應症分類，關注的重點集中在腫瘤學和類風濕性關節炎領域。在腫瘤學領域，重點關注白血病和淋巴瘤患者群體，因為機制證據和類風濕性關節炎，重點在於區分中度和重度疾病狀態，並調整對安全性監測和比較證據的預期。

按治療類別進行細分可以進一步明確其市場定位。奧拉諾芬被歸類於更廣泛的緩解疾病抗風濕藥物（DMARDs）類別中，而DMARDs是金製劑的一個細分領域。這促使人們將其與生物製藥、傳統DMARDs和標靶合成藥物進行比較。這些比較會影響臨床試驗終點、相關人員經常要求的頭對頭資料類型，以及支持實際應用的真實世界證據。

不同分銷管道的差異對於營運和患者用藥都至關重要。醫院、線上藥局和零售藥局的採購週期、庫存管理方式以及與患者的接觸點各不相同，這些都會影響藥品分發策略和臨床醫生的處方行為。最終用戶細分（例如居家醫療機構與醫院和專科診所）也決定了安全有效用藥所需的包裝、給藥便利性和支援服務。最後，劑量強度細分（通常在 3 毫克和 6 毫克之間）為劑量演算法、治療監測計劃和耐受性比較提供了基礎。整合這些多層次的細分因素，有助於相關人員改善臨床證據產生、供應鏈和實施策略，從而更好地反映真實的醫療路徑。

來自美洲、歐洲、中東和非洲以及亞太地區的區域性洞察凸顯了奧拉諾芬臨床應用、監管細微差別和准入趨勢方面的區域差異

區域差異將影響奧拉諾芬的臨床應用、監管預期和供應策略。在美洲，臨床開發往往由研究者主導的大型計畫和密集的學術機構網路推動，這既有利於快速驗證檢驗，也需要與支付方的證據要求和醫院採購的實際考慮高度契合。

在歐洲、中東和非洲地區，各國和各地區的法規結構和報銷途徑差異顯著，導致證據要求和進入時間各不相同。在這一廣大區域內運作的相關人員必須應對不同的衛生技術評估流程、多樣化的定價趨勢以及影響新型療法或老藥新用療法推廣應用的臨床實踐模式。

亞太地區正經歷著獨特的促進因素，包括多個國家臨床試驗能力的快速擴張、強大的生產能力以及多元化的醫保報銷環境。這些因素為區域生產夥伴關係、設計完善的臨床試驗的快速患者招募以及滿足多項監管和臨床要求的證據整合創造了機會。在所有地區，本地供應鏈結構、分銷合作夥伴以及臨床醫生教育舉措對於將臨床證據轉化為可惠及患者的有效治療方案至關重要。

從公司層面深入了解奧拉諾芬：研發重點、授權和合作活動、生產和供應方式以及差異化策略

企業行動和策略定位對於推動奧拉諾芬計畫從概念階段邁向臨床試驗和更廣泛的應用至關重要。各機構的研發重點不盡相同，有的機構優先進行機制研究和早期臨床試驗，有的機構則側重於後期對比研究，以滿足臨床醫生和支付方的證據需求。許可和夥伴關係活動常被用於加速研發或擴大生產和分銷能力，而無需完全建立內部基礎設施。

生產和供應策略也是企業差異化的領域。一些公司投資於垂直整合，以確保關鍵活性藥物成分的穩定供應，而其他公司則依賴契約製造組織或分散的供應商網路，這些網路可以根據需求變化進行調整。配方、包裝和劑量決策不僅影響臨床通訊協定，還影響生產批量、庫存策略以及產品是否適合分銷到醫院、零售和居家醫療機構。

競爭優勢往往體現在證據基礎的品質和針對性、供應承諾的力量以及相關人員參與的有效性。那些積極主動地將臨床計畫與實際需求結合、確保供應結構穩健、並與臨床網路建立合作關係的機構，更有可能保留市場選擇權並減少實施過程中的阻力。這些企業層面的選擇將決定奧拉諾芬從研究到成為可行治療方案的路徑。

加強奧拉諾芬研發路徑、保障供應鏈、最佳化試驗設計、改善臨床可近性的實用建議

產業領導者應採取務實且優先的行動，使科學研究潛力與營運和市場准入的實際情況相契合。首先，應有目的地建立證據策略：申辦方應儘早明確對臨床醫師和付款者最為重要的臨床終點和真實世界終點，並設計能夠產生適合這些相關人員的比較和轉化數據的研究。這有助於減少後續阻力，並在結果積極時支持快速應用於臨床實踐。

其次，必須將供應鏈穩健性作為策略重點。各組織應梳理關鍵供應商，評估單一來源的脆弱性，並在適當情況下制定替代採購或近岸外包計畫。這些措施將確保臨床項目和患者用品的持續供應，即使在關稅和貿易環境不斷變化的情況下也是如此。

第三，產品和服務設計必須反映分銷和最終用戶的需求。包裝、給藥方案和病患支援服務應根據醫院、專科診所和居家醫療環境進行客製化，以最佳化依從性和安全性。最後，相關人員應採取合作方式，透過許可、策略聯盟和研究人員聯盟等途徑共用風險、獲取專業知識並加速實證實踐。優先採取這些行動將提高負責任且可擴展的實施的可能性，並最大限度地減少營運中斷。

調查方法結合了有針對性的初步訪談、系統性的二手研究和嚴謹的三角驗證，以檢驗不同群體和地區的研究結果。

我們的研究途徑整合了多方面的證據來源和檢驗步驟，以確保分析的嚴謹性和相關性。主要研究包括對臨床醫生、供應鏈專業人員、監管顧問和試驗主管進行有針對性的保密訪談，以收集有關臨床假設、營運限制和證據需求的第一手資訊。這些訪談旨在揭示不同適應症、治療領域和最終使用環境中的實際障礙和潛在的緩解措施。

二次研究包括對同儕審查文獻、監管指導文件、臨床試驗註冊庫和上市公司揭露資訊進行系統性回顧，以整合作用機制理解、安全性數據和計畫趨勢。隨後，對一級研究和二次研究的資訊進行三角驗證：識別出共同的主題，檢驗分歧的觀點重新置於背景之中，並透過多個獨立資訊來源檢驗關鍵結論。

在整個研究過程中，我們始終關注細分市場和區域的具體特徵，以確保我們的結論能夠反映臨床適應症、治療領域、通路、最終用戶、劑量和地理等方面的差異。這種多層次的調查方法能夠提供實際的見解，讓相關人員應用於臨床規劃、供應決策和策略合作。

臨床趨勢、政策和供應風險、細分市場機會以及相關人員的行動被整合起來，以得出負責任地推廣奧拉諾芬的統一結論。

新出現的證據表明，奧拉諾芬正逐漸成為一種需要臨床、監管和營運等多領域協同合作的藥物，其定位也需要進一步擴展。在臨床方面，奧拉諾芬同時關注腫瘤和類風濕性關節炎，這既凸顯了其潛在適應症的廣泛性，也強調了製定針對特異性適應症的證據策略的必要性。在營運方面，分銷管道和終端用戶環境的差異表明，製劑、包裝和支援服務將對藥物的實際應用產生重大影響。

政策和供應方面的考量同等重要。關稅趨勢、採購慣例和製造地都會影響大規模部署和持續測試的能力。應對這些因素需要積極主動的供應計劃、靈活的採購管道和合約保障措施，以確保即使在貿易和物流波動時期也能獲得供應。

整體而言，最有效的因應措施是採取多學科協作的方式。申辦方和生產者應使研究設計與營運物流和支付方合作相協調，醫療系統應制定臨床路徑，以反映劑量、給藥途徑和證據標準的差異。透過將檢驗的臨床優先事項、穩健的供應鏈和清晰的相關人員溝通置於戰略核心，各機構將能夠負責任地推進其金諾芬項目，並將科學潛力轉化為切實的患者獲益。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 越來越多的臨床證據表明，金諾芬可用於治療卵巢和胃癌等腫瘤。
  • 非專利處方藥名奧拉諾芬製劑的推出降低了價格並擴大了市場進入。
  • 生技公司與學術機構進行策略合作，研究金諾芬在神經退化性疾病的應用
  • 罕見疾病中奧拉諾芬再利用的監管核准途徑和快速核准程序
  • 一項真實世界研究證實了金諾芬作為抗菌藥物在仿單標示外使用中的安全性和有效性。
  • 供應鏈挑戰和黃金採購對阿諾芬生產成本和進度的影響
  • 在奧拉諾芬類風濕性關節炎患者的 II 期試驗取得正面結果後，投資人興趣激增。
  • 奈米顆粒製劑技術的進步提高了金諾芬的標靶遞送和生物利用度。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按適應症分類的奧拉諾芬市場

  • 腫瘤學
    • 白血病
    • 淋巴瘤
  • 類風濕性關節炎
    • 緩和
    • 嚴重

9. 按治療類別分類的奧拉諾芬市場

  • DMARDs
    • 生物製藥
    • 傳統的
    • 標靶定向藥物
  • 黃金製劑

第10章 金諾芬市場依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 奧拉諾芬市場（以最終用戶分類）

  • 居家醫療設施
  • 醫院
  • 專科診所

12. 以劑量強度分類的奧拉諾芬市場

  • 3mg
  • 6mg

第13章 奧拉諾芬市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 奧拉諾芬市場（依集團分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國奧拉諾芬市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Teva Pharmaceutical Industries Ltd
    • Sandoz International GmbH
    • Viatris Inc
    • Amneal Pharmaceuticals LLC
    • Fresenius Kabi AG
    • Aurobindo Pharma Ltd
    • Dr. Reddy's Laboratories Ltd
    • Apotex Inc
    • Hi-Tech Pharmacal Co., Inc
    • Sagent Pharmaceuticals Inc
Product Code: MRR-F97DD5A7D98B

The Auranofin Market is projected to grow by USD 322.96 million at a CAGR of 4.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 218.99 million
Estimated Year [2025] USD 230.02 million
Forecast Year [2032] USD 322.96 million
CAGR (%) 4.97%

Auranofin repositioning across oncology and rheumatoid arthritis signaling cross-disciplinary opportunities to enhance therapeutic development and outcomes

Auranofin has emerged from a longstanding therapeutic history with renewed interest driven by expanding clinical signals and a clearer understanding of its pharmacology. Initially developed and deployed in the context of rheumatologic indications, its mechanisms of action have attracted attention for potential anticancer and immunomodulatory uses. This repositioning has prompted a wide array of stakeholders-clinical investigators, formulary committees, manufacturers, and payers-to reassess where auranofin fits within contemporary treatment frameworks.

As clinical programs evolve, the drug's profile is being examined in parallel pathways: continued relevance in immune-mediated disease and growing exploration within oncology. This dual trajectory has introduced novel considerations around dosing strategies, safety monitoring, and comparative positioning relative to alternative therapeutic classes. At the same time, changes in regulatory expectations and payer scrutiny are influencing development strategies and evidence generation plans.

Taken together, these dynamics create both opportunity and complexity. Organizations engaging with auranofin must balance the demand for robust clinical validation with practical imperatives such as reliable supply, appropriate distribution arrangements, and clear value communication for clinicians and patients. The introduction establishes why auranofin's renewed relevance warrants careful strategic planning across clinical, operational, and access-related domains.

Scientific advances, regulatory shifts, and commercialization trends converging to redefine auranofin's clinical positioning and trial design priorities

The landscape for auranofin is undergoing several transformative shifts that span science, regulation, and commercial execution. On the scientific front, advances in understanding redox biology, protein homeostasis, and immune modulation have clarified plausible mechanisms through which auranofin could exert benefit beyond its original indication. These mechanistic insights have coincided with more sophisticated biomarkers and translational models, which together are shaping the design of contemporary clinical programs and hypothesis-driven trials.

Regulatory pathways have also recalibrated in ways that matter for repositioned drugs. Agencies increasingly encourage adaptive trial designs and real-world evidence integration when safety profiles are well-characterized, creating both pathways and expectations for sponsors. At the same time, heightened attention to benefit-risk balance and cost-effectiveness means that evidentiary strategies must be tightly aligned to payer and clinician needs from an earlier stage.

Commercially, shifts in distribution logistics, sourcing strategies, and manufacturer partnerships are influencing how developers think about scale-up and access. Strategic alliances-ranging from licensing agreements to contract manufacturing relationships-provide routes to secure supply, while collaborative research models enable more rapid validation of new indications. Together, these scientific, regulatory, and commercial inflections are redefining how stakeholders prioritize investments and allocate resources in support of auranofin's next-generation programs.

Anticipated United States tariff adjustments in 2025 and their effects on auranofin supply chain resilience, procurement costs, and clinical trial operations

Changes to tariff policy in the United States in 2025 have implications for pharmaceutical supply chains that extend to drugs like auranofin, particularly where active pharmaceutical ingredients, packaging, or secondary components are sourced internationally. Tariff adjustments can alter procurement economics for manufacturers and contract partners, prompting reassessments of sourcing locations, supplier contracts, and inventory strategies. These operational responses often happen alongside efforts to shore up resilience and reduce exposure to single-source dependencies.

Clinical research operations are also affected by shifts in import/export costs. Increased tariffs on raw materials or finished goods can influence trial budgets and logistics, especially for multicenter studies that rely on centralized supply distribution. Sponsors may need to modify shipment schedules, identify alternative vendors, or engage additional contingency planning to preserve trial timelines and data integrity. Importantly, procurement tactics that emphasize diversification and nearshoring can mitigate volatility but require lead time to implement.

Finally, payers and providers may experience downstream effects, as procurement cost pressures can influence formulary decisions and hospital purchasing agreements. Organizations considering expanded development or wider deployment of auranofin should therefore integrate tariff-related scenarios into supply planning, contract negotiations, and clinical operations so that contingency measures are in place to maintain continuity of care and research momentum.

Key segmentation insights revealing drivers of clinical application and positioning for auranofin across indications, therapy classes, channels, and dosages

Segment-level dynamics provide essential context for how auranofin is being evaluated and deployed in clinical and operational settings. When viewed by indication, the portfolio of interest clusters into oncology and rheumatoid arthritis; within oncology, focused efforts concentrate on leukemia and lymphoma populations where mechanistic rationale and preliminary data suggest potential benefit, while within rheumatoid arthritis attention differentiates between moderate and severe disease states to tailor safety monitoring and comparative evidence expectations.

Therapeutic class segmentation further clarifies positioning. Auranofin sits in the broader class of disease-modifying antirheumatic drugs and in the niche of gold compounds, prompting comparisons to biologics, conventional DMARDs, and targeted synthetic agents. These comparisons influence clinical trial endpoints and the kinds of head-to-head data that stakeholders often request, as well as the profile of real-world evidence that will support adoption in practice.

Distribution channel distinctions matter operationally and for patient access. Hospital pharmacies, online pharmacies, and retail pharmacies each have different procurement cycles, inventory management practices, and patient touchpoints, which in turn shape fulfillment strategies and clinician prescribing behavior. End-user segmentation-distinguishing home care settings from hospitals and specialty clinics-also drives packaging, dosing convenience, and support services that may be necessary for safe and effective use. Finally, dosage strength segmentation, typically between 3mg and 6mg formulations, underpins dosing algorithms, therapeutic monitoring plans, and comparative tolerability discussions. Integrating these layered segments enables stakeholders to make nuanced decisions about clinical evidence generation, supply arrangements, and adoption strategies that reflect real-world care pathways.

Regional insights across Americas, EMEA, and Asia-Pacific that highlight differences in clinical adoption, regulatory nuance, and access dynamics for auranofin

Regional variations shape clinical adoption, regulatory expectations, and supply strategies for auranofin. In the Americas, clinical development tends to be driven by extensive investigator-led programs and a dense network of academic centers, which supports rapid hypothesis testing but also requires strong alignment with payer evidence requirements and practical considerations for hospital procurement.

In Europe, Middle East & Africa, regulatory frameworks and reimbursement pathways vary markedly by country and region, creating a mosaic of evidence needs and access timelines. Stakeholders operating in this broader region must navigate heterogeneous HTA processes, diverse pricing dynamics, and distinct clinical practice patterns that influence how new or repurposed therapies are adopted.

Asia-Pacific exhibits its own set of drivers: rapid expansion of clinical trial capacity in several countries, strong manufacturing capabilities, and varied reimbursement environments. These factors create opportunities for regional manufacturing partnerships, accelerated enrollment for appropriately designed trials, and a need to calibrate evidence packages so they meet multiple regulatory and clinical expectations. Across all regions, local supply chain arrangements, distribution partners, and clinician education initiatives are critical to translating clinical evidence into practical availability for patients.

Company-level insights on R&D focus, licensing and partnership activity, manufacturing and supply approaches, and differentiation strategies around auranofin

Company behavior and strategic positioning are central to how auranofin programs progress from concept to clinic and to broader availability. Research and development focus varies across organizations, with some prioritizing mechanistic exploration and early-phase trials while others emphasize late-stage comparative studies that address clinician and payer evidence needs. Licensing and partnership activity frequently emerge as mechanisms to accelerate development or to expand manufacturing and distribution capabilities without the need for fully internalized infrastructure.

Manufacturing and supply strategies are another area of differentiation. Some companies invest in vertical integration to secure key active pharmaceutical ingredient flows, while others rely on contract manufacturing organizations and distributed supplier networks that can be reconfigured as demand evolves. Decisions about formulation, packaging, and dosage strengths influence not just clinical protocols but also production batch sizes, inventory strategies, and distribution suitability for hospital, retail, or home care settings.

Competitive differentiation often centers on the quality and specificity of the evidence base, the robustness of supply commitments, and the effectiveness of stakeholder engagement. Organizations that proactively align clinical programs with real-world needs, secure resilient supply arrangements, and cultivate collaborative relationships with clinical networks tend to preserve optionality and reduce implementation friction. These corporate-level choices define the trajectory of auranofin from investigational programs to practical therapeutic options.

Actionable recommendations to strengthen development pathways, secure supply chains, refine trial design, and improve clinical access for auranofin

Industry leaders should adopt pragmatic, prioritized actions to align scientific promise with operational and access realities. First, evidence strategies should be purpose-built: sponsors ought to define the clinical and real-world endpoints that matter most to clinicians and payers early, and design trials that generate comparative and translational data suited to those stakeholders. This reduces downstream friction and supports more rapid assimilation into clinical practice when results are positive.

Second, supply chain robustness must be elevated to a strategic priority. Organizations should map critical suppliers, assess single-source vulnerabilities, and develop alternative sourcing or nearshoring plans where appropriate. These steps enable continuity for both clinical programs and patient supply while tariffs and trade dynamics evolve.

Third, distribution and end-user needs must inform product and service design. Packaging, dosing regimens, and patient support services should be tailored to hospitals, specialty clinics, and home care settings to optimize adherence and safety. Finally, stakeholders should pursue collaborative approaches-whether through licensing, strategic partnerships, or investigator consortia-to share risk, access specialized capabilities, and accelerate evidence generation. Prioritizing these actions will improve the likelihood of responsible, scalable adoption and minimize operational disruptions.

Methodology combining targeted primary interviews, structured secondary research, and rigorous triangulation to validate insights across segments and regions

The research approach integrates multiple evidence streams and validation steps to ensure analytic rigor and relevance. Primary research included targeted, confidential interviews with clinicians, supply chain specialists, regulatory advisors, and trial operations leads to capture first-hand perspectives on clinical hypotheses, operational constraints, and evidence needs. These interviews were structured to surface practical barriers and potential mitigations across indications, therapeutic classes, and end-use settings.

Secondary research comprised a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to synthesize mechanistic understanding, safety data, and programmatic trends. Findings from primary and secondary sources were then subjected to triangulation: convergent themes were identified, divergent viewpoints were traced back to context, and key assertions were tested against multiple independent information points.

Throughout the process, attention was given to segment and regional specificity so that conclusions reflect the differences between clinical indications, therapeutic classes, distribution pathways, end users, and dosage strengths, as well as geographic distinctions. This layered methodology supports actionable insights that stakeholders can apply to clinical planning, supply decisions, and strategic partnerships.

Integrated conclusion synthesizing clinical momentum, policy and supply risks, segmentation opportunities, and stakeholder actions to responsibly advance auranofin

The evidence gathered points to auranofin's evolving role as a candidate for repositioning that demands coordinated attention across clinical, regulatory, and operational domains. Clinically, the dual focus on oncology and rheumatoid arthritis highlights both the breadth of potential applications and the need for indication-specific evidence strategies. Operationally, distribution channel distinctions and end-user settings underscore that formulation, packaging, and support services materially affect real-world usability.

Policy and supply considerations are equally consequential. Tariff dynamics, procurement practices, and manufacturing footprints will influence the feasibility of broad deployment and trial continuity. Responding to these factors requires proactive supply planning, flexible sourcing, and contractual safeguards that preserve access during periods of trade or logistic volatility.

Taken together, the most effective responses will be multidisciplinary: sponsors and manufacturers must coordinate trial design with operational logistics and payer engagement, while health systems should prepare clinical pathways that reflect differences in dosing, administration settings, and evidence thresholds. By centering strategy on validated clinical priorities, resilient supply arrangements, and clear stakeholder communication, organizations can responsibly advance auranofin programs and translate scientific potential into meaningful patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising clinical evidence for auranofin repurposing in oncology indications such as ovarian and gastric cancers
  • 5.2. Emergence of generic auranofin formulations driving price drops and wider market access
  • 5.3. Strategic partnerships between biotech firms and academic centers for auranofin research in neurodegenerative diseases
  • 5.4. Regulatory pathways and expedited approvals for repurposed auranofin in rare disease indications
  • 5.5. Real-world evidence studies highlighting auranofin safety and efficacy in off-label antimicrobial applications
  • 5.6. Supply chain challenges and raw gold sourcing impact on auranofin manufacturing costs and timelines
  • 5.7. Investor interest surge following positive phase II trial results of auranofin in rheumatoid arthritis refractory patients
  • 5.8. Advances in nanoparticle formulations to enhance auranofin targeted delivery and bioavailability profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Auranofin Market, by Indication

  • 8.1. Oncology
    • 8.1.1. Leukemia
    • 8.1.2. Lymphoma
  • 8.2. Rheumatoid Arthritis
    • 8.2.1. Moderate
    • 8.2.2. Severe

9. Auranofin Market, by Therapeutic Class

  • 9.1. DMARDS
    • 9.1.1. Biologics
    • 9.1.2. Conventional
    • 9.1.3. Targeted Synthetic
  • 9.2. Gold Compounds

10. Auranofin Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Auranofin Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Auranofin Market, by Dosage Strength

  • 12.1. 3mg
  • 12.2. 6mg

13. Auranofin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Auranofin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Auranofin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Teva Pharmaceutical Industries Ltd
    • 16.3.2. Sandoz International GmbH
    • 16.3.3. Viatris Inc
    • 16.3.4. Amneal Pharmaceuticals LLC
    • 16.3.5. Fresenius Kabi AG
    • 16.3.6. Aurobindo Pharma Ltd
    • 16.3.7. Dr. Reddy's Laboratories Ltd
    • 16.3.8. Apotex Inc
    • 16.3.9. Hi-Tech Pharmacal Co., Inc
    • 16.3.10. Sagent Pharmaceuticals Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 301. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GCC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. GCC AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. GCC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. GCC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 308. GCC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 309. GCC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 310. GCC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 311. GCC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 312. GCC AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 313. GCC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. GCC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. GCC AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. GCC AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 318. GCC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 341. BRICS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. BRICS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 355. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. G7 AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 358. G7 AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 359. G7 AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 360. G7 AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 361. G7 AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 362. G7 AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 363. G7 AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 364. G7 AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 365. G7 AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
  • TABLE 366. G7 AURANOFIN MARKET SIZE, BY DMARDS, 2025-2032 (USD MILLION)
  • TABLE 367. G7 AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 368. G7 AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 369. G7 AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 370. G7 AURANOFIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 371. G7 AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 372. G7 AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 373. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 374. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 375. NATO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 376. NATO AURANOFIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)

TABLE